Blog
Blog
AI-driven Advancements in Life Sciences
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life Sciences is honored to be recognized as a Leader in this comprehensive assessment, a distinction rooted…
Filter posts by:
Blog
Part II: Non-Traditional Players Attempting Entry into the Healthcare Sector
Executive Summary Trinity’s Take: Walmart’s partnership with Novo Nordisk promises key benefits to diabetes patients (e.g., cost savings, improved access), but the extent of the benefit remains to be seen. Instead, the partnership is likely to prompt a response by...
Blog
Part I: Non-Traditional Players Attempting Entry Into the Healthcare Sector
Executive Summary Trinity’s take: Non-traditional players that have been successful in tapping into the healthcare sector seem to follow a strategy of patience, acquirement of ample infrastructure and expertise, sufficient capital, and beneficial partnerships and acquisitions. On the other hand, the...
Blog
Exploring the Impact of COVID-Driven Trends on the US Healthcare Landscape
Executive Summary Trinity’s Take: A review of changes since March 2020 to patients / providers, payers, clinical research, and pharmaceutical distribution within the US reveals that there is increased use and coverage of telemedicine, interest in more targeted clinical research,...
Blog
Verily to Acquire SignalPath, Expanding the Company’s Clinical Research Capabilities
Verily recently announced its first major acquisition, a software platform known as SignalPath. SignalPath’s flagship software, TrialPath, digitizes and modulates individual protocols in a clinical trial, from budgeting to tracking point-of-care communication. The acquisition would fold SignalPath into Baseline, Verily’s clinical research...
Blog
What Market Access Opportunities Exist for Rare Disease Products in China? An Analysis of Rare Disease Product Inclusion in the 2020 NRDL
Executive Summary Trinity’s Take: Due to the rapidly evolving rare disease policy environment in China, manufacturers should prepare to take a flexible approach to their rare disease product market access strategy. This would include considering alternative funding opportunities outside of the NRDL...
Blog
What Market Access Opportunities Exist for Oncology Products in China? An Analysis of Oncology Product Inclusion in the 2020 NRDL
Executive Summary Trinity’s Take: While the NRDL presents increasing reimbursement opportunities for oncology products in China, pricing restrictions will remain as a key challenge. In order to defend pricing in NRDL negotiations, manufacturers should consider targeting indications with high unmet needs...
